Physician profile

Byron P Dubow

Urology · Templeton, CA

NPI 1710365671

$6,046.63

in general payments reported to CMS, 2019-2025

45 companies · $1,429 in 2025

The $1,429 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

See the full distribution for Urology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,215.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $657.83 2020-2025 Lupron Depot, Botox
Astellas Pharma US INC $481.62 2022-2025 Xtandi, Myrbetriq, Veozah
Myriad Genetic Laboratories, INC. $470.05 2021-2025 Prolaris, Myrisk
Sumitomo Pharma America, INC. $457.08 2023-2025 Gemtesa, Orgovyx
Janssen Biotech, INC. $390.15 2022-2025 Erleada, Rybrevant, Carvykti
Pfizer INC. $375.03 2021-2025
Dendreon Pharmaceuticals LLC $275.84 2019-2024 Provenge
Procept Biorobotics Corporation $274.26 2023-2025 Aquabeam Robotic System
Tolmar Pharmaceuticals, INC. $263.02 2020-2022
Teleflex LLC $198.89 2023-2025 Barrigel, Urolift
Coloplast Corp $156.27 2019-2025 Titan, Altis
Axonics, INC. $155.80 2022-2024 Axonics
Bluewind Medical $147.26 2025 Revi
Foundation Medicine, INC. $127.02 2022-2023 Foundationone Liquid Cdx
Merck Sharp & Dohme LLC $122.69 2020-2025 Lynparza
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Sun Pharmaceutical Industries INC. $96.98 2024-2025
Bayer Healthcare Pharmaceuticals INC. $96.76 2022-2025
Endo Pharmaceuticals INC. $95.02 2021-2024 Xiaflex, Aveed
Urogen Pharma, INC. $91.98 2022-2025
Palette Life Sciences, INC. $91.57 2022
Ferring Pharmaceuticals INC. $84.85 2024-2025 Adstiladrin
Amgen INC. $83.10 2020-2022
Allergan, INC. $81.89 2021-2022
Astrazeneca Pharmaceuticals LP $80.85 2022-2023 Lynparza
Accord Healthcare, INC. $79.05 2024
Boston Scientific Corporation $78.83 2019-2025 Spaceoar Vue System - 10ml, Ams 700
Edap Technomed INC $61.19 2025
Antares Pharma, INC. $51.61 2024 Xyosted
Philips North America LLC $45.42 2022
Progenics Pharmaceuticals, INC. $44.63 2024-2025
Urovant Sciences INC $40.58 2022
Smith+Nephew, INC. $34.10 2023 Stravix Pl
Verity Pharmaceuticals INC. $30.05 2023 Trelstar
Tolmar, INC. $24.58 2023
Blue Earth Diagnostics $23.51 2023
Janssen Scientific Affairs, LLC $23.34 2023 Balversa, Erleada
Olympus America INC. $22.92 2025 Itind System
Angiodynamics, INC. $20.85 2023 Nanoknife
Endo USA, INC. $19.44 2024 Xiaflex
Vertex Pharmaceuticals Incorporated $17.40 2025
Immunitybio, INC. $16.73 2025
Pacira Pharmaceuticals Incorporated $16.16 2021
Alnylam Pharmaceuticals INC. $15.77 2025 Oxlumo
Becton, Dickinson and Company $12.58 2019
Srs Medical Systems, INC. $12.08 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Byron P Dubow

$6,046.63

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $1,429 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/2786216/byron-p-dubow

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.